Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
22
States / cities
Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Terminated Not applicable Interventional Results available

Melatonin for Circadian Sleep Disorders in the Blind

NCT00911053
Conditions
Insomnia, Blindness, Daytime Sleepiness
Interventions
Melatonin, Regular Sleep Schedule, Light
Drug · Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 100 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Apnea, Sleep Disorders, Overweight and/or Obesity
Interventions
Berobenatide, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Bradenton, Florida • Tomball, Texas
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Conditions
Prader-Willi Syndrome
Interventions
Pitolisant tablet, Placebo tablet
Drug · Other
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
6 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 16 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Project REST: Club Sports

NCT07103759
Conditions
Poor Quality Sleep
Interventions
Refrain from caffeine techniques, Project REST Platform
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Idiopathic Hypersomnia, Excessive Daytime Sleepiness
Interventions
Pitolisant
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
32
States / cities
Los Angeles, California • San Ramon, California • Brandon, Florida + 29 more
Conditions
Narcolepsy Type 2
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, ALKS 2680 Dose 3, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Cullman, Alabama • Phoenix, Arizona • Los Angeles, California + 20 more
Conditions
Obstructive Sleep Apnea
Interventions
Bright light therapy glasses
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Myotonic Dystrophy 1, Excessive Daytime Sleepiness
Interventions
Pitolisant Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
11
States / cities
Irvine, California • Aurora, Colorado • Tampa, Florida + 8 more
Conditions
Obstructive Sleep Apnea
Interventions
TAK-925, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 67 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Alabaster, Alabama • Glendale, Arizona • Little Rock, Arkansas + 15 more
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work Disorder

NCT04788953
Conditions
Excessive Sleepiness, Shift-work Disorder
Interventions
Solriamfetol Oral Tablet, Placebo
Drug
Lead sponsor
Charles A. Czeisler, PhD, MD
Other
Eligibility
18 Years to 64 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Daytime Sleepiness
Interventions
Track 1, Track 2
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
20 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Narcolepsy
Interventions
SUVN-G3031, Placebo
Drug
Lead sponsor
Suven Life Sciences Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 30 more
Conditions
Narcolepsy, Cataplexy, Excessive Daytime Sleepiness
Interventions
AXS-12 (reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
15 Years to 75 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
24
States / cities
Phoenix, Arizona • Boulder, Colorado • Colorado Springs, Colorado + 20 more
Conditions
Idiopathic Hypersomnia, Narcolepsy
Interventions
JZP258 (XYWAV)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
29
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 25 more
Conditions
Narcolepsy Type 1, Narcolepsy Type 2
Interventions
cleminorexton, Placebo
Drug
Lead sponsor
Centessa Pharmaceuticals (UK) Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Colorado Springs, Colorado • Brandon, Florida + 17 more
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Phoenix, Arizona • St. Petersburg, Florida • Atlanta, Georgia + 6 more
Withdrawn No phase listed Observational Accepts healthy volunteers

Start Times and Restful Sleep

NCT04049682
Conditions
Excessive Daytime Somnolence, Sleep Deprivation
Interventions
Delayed School Start Time
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
13 Years to 18 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Diego, California
Conditions
Narcolepsy, Cataplexy Narcolepsy, Excessive Sleepiness
Interventions
AXS-12 (Reboxetine), Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Birmingham, Alabama • Alameda, California • Santa Ana, California + 11 more
Conditions
Hypersomnia, Narcolepsy, Traumatic Brain Injury
Interventions
Sodium Oxybate Oral Solution [Xyrem]
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Narcolepsy
Interventions
Xyrem, Xyrem Placebo, Modafinil at established dose, Modafinil (Placebo)
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
36
States / cities
Phoenix, Arizona • Fullerton, California • Los Angeles, California + 29 more
Suspended Not applicable Interventional Accepts healthy volunteers

Light Exposure to Treat Sleep Disruption in Older People

NCT00427323
Conditions
Sleep Initiation and Maintenance Disorders, Circadian Rhythm Sleep Disorders, Hypersomnia
Interventions
light exposure
Procedure
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Nocturia, Daytime Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Durham, North Carolina